The organometallic half-sandwich Ru(II) arene anticancer complex [(eta(6)-fluorene)Ru(en)Cl]PF(6) () has been synthesized in high yield and purity on a micromole scale with incorporation of the beta-emitting radioisotope (106)Ru (half-life = 1.01 y) using a refined procedure involving conversion of RuCl(3) into [(eta(6)-fluorene)RuCl(2)](2), and then [(eta(6)-fluorene)Ru(CH(3)CN)(2)Cl]PF(6) as intermediates. Distribution studies 0.25 h post i.v. injection of (106)Ru- at a dose of 25 mg kg(-1) show that (106)Ru is well distributed throughout the tissues of a rat. This appears to be the first report of the radiolabelling of a potential ruthenium antitumour agent for distribution/biological studies.
No takes yet. Share an insight, caveat, or question.
Hoeschele et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: